IL143349A0 - Azepinoindole derivatives, the production and use thereof - Google Patents

Azepinoindole derivatives, the production and use thereof

Info

Publication number
IL143349A0
IL143349A0 IL14334900A IL14334900A IL143349A0 IL 143349 A0 IL143349 A0 IL 143349A0 IL 14334900 A IL14334900 A IL 14334900A IL 14334900 A IL14334900 A IL 14334900A IL 143349 A0 IL143349 A0 IL 143349A0
Authority
IL
Israel
Prior art keywords
production
azepinoindole derivatives
azepinoindole
derivatives
Prior art date
Application number
IL14334900A
Other languages
English (en)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946289A external-priority patent/DE19946289A1/de
Priority claimed from DE10039610A external-priority patent/DE10039610A1/de
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL143349A0 publication Critical patent/IL143349A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL14334900A 1999-09-28 2000-09-15 Azepinoindole derivatives, the production and use thereof IL143349A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19946289A DE19946289A1 (de) 1999-09-28 1999-09-28 Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10039610A DE10039610A1 (de) 2000-08-09 2000-08-09 Azepinoindol-Derivate, deren Herstellung und Anwendung
PCT/EP2000/009024 WO2001023390A2 (de) 1999-09-28 2000-09-15 Azepinoindol-derivate, deren herstellung und anwendung

Publications (1)

Publication Number Publication Date
IL143349A0 true IL143349A0 (en) 2002-04-21

Family

ID=26006691

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14334900A IL143349A0 (en) 1999-09-28 2000-09-15 Azepinoindole derivatives, the production and use thereof

Country Status (17)

Country Link
EP (1) EP1183259A2 (de)
JP (1) JP2003510328A (de)
KR (1) KR20010087401A (de)
CN (1) CN1374961A (de)
AU (1) AU1271201A (de)
BG (1) BG105650A (de)
BR (1) BR0007174A (de)
CA (1) CA2352194A1 (de)
CZ (1) CZ20012373A3 (de)
HK (1) HK1048999A1 (de)
HU (1) HUP0104917A3 (de)
IL (1) IL143349A0 (de)
NO (1) NO20012567L (de)
PL (1) PL347885A1 (de)
SK (1) SK8842001A3 (de)
TR (1) TR200101499T1 (de)
WO (1) WO2001023390A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140936B1 (de) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclische inhibitoren von poly(adp-ribose) polymerasen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1339402B1 (de) 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
US7026311B2 (en) * 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
ATE546539T1 (de) 2002-07-26 2012-03-15 Basf Plant Science Gmbh Revertierung der negativ-selektiven wirkung von negativen markerproteinen als selektionsverfahren
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
ATE541043T1 (de) 2005-03-08 2012-01-15 Basf Plant Science Gmbh Expressionsverstärkende intron-sequenz
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
KR20100059950A (ko) 2007-09-14 2010-06-04 아스트라제네카 아베 프탈라지논 유도체
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
JP5922029B2 (ja) 2009-11-27 2016-05-24 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー キメラエンドヌクレアーゼおよびその使用
AU2010325549B2 (en) 2009-11-27 2017-04-20 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
WO2011064751A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
NZ604035A (en) 2010-06-04 2015-02-27 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
KR101896567B1 (ko) 2015-07-23 2018-09-07 인스티튜트 큐리 암 치료를 위한 디베이트 분자와 parp 억제제의 병용 용도
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
WO2018218025A1 (en) * 2017-05-24 2018-11-29 The Trustees Of The University Of Pennsylvania Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy
EP3765613A1 (de) 2018-03-13 2021-01-20 Onxeo Dbait-molekül gegen erworbene resistenz in der behandlung von krebs
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
KR20210125024A (ko) * 2019-02-02 2021-10-15 치아타이 티안큉 파마수티컬 그룹 주식회사 Parp 억제제로서의 인돌로 헵타밀 옥심 유사체
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021318572A1 (en) * 2020-07-31 2023-02-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as PARP inhibitor and method for preparing same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011644A1 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
EP1140936B1 (de) * 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclische inhibitoren von poly(adp-ribose) polymerasen
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas

Also Published As

Publication number Publication date
HK1048999A1 (zh) 2003-04-25
HUP0104917A3 (en) 2002-12-28
CN1374961A (zh) 2002-10-16
SK8842001A3 (en) 2002-01-07
KR20010087401A (ko) 2001-09-15
NO20012567L (no) 2001-06-25
BR0007174A (pt) 2001-09-04
CA2352194A1 (en) 2001-04-05
TR200101499T1 (tr) 2002-09-23
WO2001023390A2 (de) 2001-04-05
WO2001023390A3 (de) 2001-12-27
BG105650A (en) 2002-02-28
JP2003510328A (ja) 2003-03-18
HUP0104917A2 (hu) 2002-04-29
NO20012567D0 (no) 2001-05-25
EP1183259A2 (de) 2002-03-06
PL347885A1 (en) 2002-04-22
AU1271201A (en) 2001-04-30
CZ20012373A3 (cs) 2002-05-15

Similar Documents

Publication Publication Date Title
IL143349A0 (en) Azepinoindole derivatives, the production and use thereof
ZA200104196B (en) Azepinoindole derivatives, the production and use thereof.
HRP20020375A2 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
ZA200203316B (en) New use and novel n-azabicyclo-amide derivatives.
PL347500A1 (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
PL344467A1 (en) Substituted indolinones, the production thereof and their use as medicaments
HUP0203290A3 (en) Indeno-, naphto-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments
SI1268522T1 (sl) Novi antagonisti lhrh, njihova priprava in uporaba kot zdravila
HK1044946A1 (zh) 依泊昔酮衍生物、其製備方法及藥物用途
ZA200001746B (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use.
EP1210084A4 (de) Pyridomorphinane, thienomorphinane und deren verwendung
FI104003B1 (fi) Stabiloitu täyteaine, sen valmistus ja käyttö
AU2011501A (en) Benzimidazoles, production thereof and the use thereof as antithrombotic
AU7563800A (en) Marsh-mallow and the marsh-mallow production technique
HU0001397D0 (en) 3-amino-3-arylpropan-1-ol derivatives, production and use thereof
HUP0103358A3 (en) N-substituted azabicycloheptane derivatives, production and use thereof
HK1061655A1 (en) Caloporoside derivatives, methods for the production thereof and their use
HUP0203455A3 (en) 2-arylquinoline derivatives, preparation and therautic use thereof
GB2350361B (en) 3,4,5-tricyanophenyl derivatives
HRP20020971A2 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-inhibitors
SI1127052T1 (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
SI1230230T1 (en) Indeno-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments
SI1372670T1 (en) Caloporoside derivatives, methods for the production thereof and their use
HUP0103099A3 (en) N-substituted azabicycloheptane derivatives, production and use thereof
SI1105388T1 (en) N-substituted azabicycloheptane derivatives, production and use thereof